Loading...

NFLR

FRX

INFLARX NV

(IFRX)

2024 6-K

Share Offering Update

7 May '26

Izicopan Development Update

6 May '26

Financial Report

6 May '26

Izicopan Developments

4 May '26

Compliance Regained

28 Apr '26

Annual Meeting Results

23 Apr '26

Research Findings

9 Apr '26

Annual Meeting Notice

2 Apr '26

Annual Results Report

19 Mar '26

Nasdaq Compliance Notice

13 Mar '26

Company Restructuring

8 Jan '26

Phase 3 Analysis Update

30 Dec '25

Positive Trial Results

10 Nov '25

Financial Report

10 Nov '25

NASDAQ Compliance Regained

12 Sep '25

Filing Report Summary

7 Aug '25

Nasdaq Compliance Notice

14 Jul '25

Accounting Change

27 Jun '25

Trial Stopped

28 May '25

Financial Update

7 May '25

Annual Meeting Results

24 Apr '25

Annual Meeting Notice

3 Apr '25

Annual Results Report

20 Mar '25

Share Offering Details

18 Feb '25

EU Approval Granted

15 Jan '25

Patient Study Dosage

20 Dec '24

Positive CHMP Opinion

15 Nov '24

Financial Report

8 Nov '24

Financial Report Update

8 Aug '24

Sales Agreement

28 Jun '24

Clinical Trial Announcement

24 Jun '24

R&D Event Announcement

5 Jun '24

COVID-19 Trial Insight

21 May '24

Quarterly Report Filed

8 May '24

Annual Meeting Results

25 Apr '24

Annual Meeting Notice

4 Apr '24

Quarterly Update

21 Mar '24

InflaRx Filing

21 Mar '24

New Commitment Program

25 Jan '24

Positive Study Results

4 Jan '24

External Links:

SEC

InflaRx N.V. reported its Full Year 2023 financial results on March 21, 2024, and hosted a conference call detailing developments in its products, including the oral C5aR inhibitor INF904 and vilobelimab for pyoderma gangrenosum. This filing is significant and carries a neutral sentiment for equity investors.

AI Assistant

INFLARX NV

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.